Latest news
Silence Therapeutics’ Divesiran Hits Phase II Goal, Sets Up Phase III PV Trial - Yahoo FinanceYahoo Finance · Tue, 11 Aug 2026 05:01:00 GMTDivesiran Eliminates Need for Phlebotomy in 88% of Patients With Polycythemia Vera - Cure TodayCure Today · Mon, 10 Aug 2026 20:53:09 GMTSilence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile - Business WireBusiness Wire · Mon, 10 Aug 2026 11:30:00 GMTSilence Therapeutics Reports Second Quarter 2026 Financial and Business Results - Business WireBusiness Wire · Mon, 10 Aug 2026 11:15:00 GMTSilence Therapeutics Shares Surge Ahead of Phase 2 SANRECO Trial Results - sekbernews.idsekbernews.id · Mon, 10 Aug 2026 11:06:04 GMTSapablursen Represents Potential Avenue for Improved Hepcidin Production in Polycythemia Vera - onclive.comonclive.com · Mon, 03 Aug 2026 18:11:54 GMT